sur Biotricity, Inc. (NASDAQ:BTCY)
Biotricity Projects Significant Improvements in Year-End Financial Results
REDWOOD CITY, CA / ACCESSWIRE / June 6, 2024 / Biotricity Inc. (NASDAQ: BTCY), a Technology-as-a-Service (TaaS) company specializing in healthcare solutions, has provided year-end financial guidance. The company forecasts meeting analyst revenue targets and surpassing loss and margin goals.
Biotricity anticipates revenue growth exceeding 24% year-over-year (YoY). Additionally, the company expects a decrease in Loss from Operations by over 40% YoY and an improvement in margins by over 10% YoY.
Dr. Waqaas Al-Siddiq, Founder and CEO, highlighted that these achievements demonstrate sustained growth and efficiency, positioning Biotricity on a path to profitability and cashflow breakeven. He emphasized the unique combination of growth, reduction in losses, and margin improvement experienced by the company.
Biotricity's success is credited to its robust business model, high adoption rates of its solutions, and operational efficiency within the cardiac market. The company continues to lead the market with its TaaS model, known for strong margins and customer retention.
R. P.Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés. Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de Biotricity, Inc.